Dr. Lippa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
909 Walnut St
Philadelphia, PA 19107Phone+1 215-955-1234Fax+1 215-923-6792
Summary
- Board certified neurologist with an international reputation in academic neurology, who has directed cognitive disorders programs for over 20 years. Currently bringing together experts from various disciplines to develop a Cognitive and Comprehensive Alzheimer’s disease clinical, research and education Center within the Farber Institute for Neuroscience and TJU department of Neurology to provide patients and families more accurate and earlier diagnosis and intervention, expand and solidify the related translational research units and develop education/training initiatives.
Clinical Expertise
- Alzheimer's disease, Alzheimer Vaccines, Vascular dementia, Lewy body dementia, Parkinson's disease, Frontotemporal lobar degeneration , Cognitive disorders, Concussion, Clinical research, Clincial trials, Behavioral neurology / Neuropsychiatry, General neurology, Geriatrics / Dementia, Movement disorders, Depressed skull fractures, Post-partum depression, Sexual aversion disorder, Diabetes
Education & Training
- University of Massachusetts Medical SchoolFellowship, Neuropathology, 1987 - 1988
- UMass Chan Medical SchoolResidency, Neurology, 1983 - 1987
- University of Massachusetts Medical SchoolClass of 1983
Certifications & Licensure
- NJ State Medical License 2018 - 2025
- PA State Medical License 1995 - 2024
- MA State Medical License 1988 - 2005
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia Start of enrollment: 2006 Nov 01
- AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
- Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 249 citationsTREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s diseaseSruti Rayaprolu, Bianca Mullen, Matt Baker, Timothy Lynch, Elizabeth Finger
Molecular Neurodegeneration. 2013-06-21 - 1951 citationsDiagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB ConsortiumIan G. McKeith, Bradley F. Boeve, Dennis W. Dickson, Glenda M. Halliday, John-Paul Taylor
Neurology. 2017-07-04 - 37 citationsCognition and amyotrophic lateral sclerosis (ALS).David J. Irwin, Carol F. Lippa, Joan M. Swearer
American Journal of Alzheimer's Disease and Other Dementias. 2007-08-01
Press Mentions
- Health: Cocoa & the Brain, Restoring Your Younger MindMay 6th, 2016
Grant Support
- International Multispecialty Conference On PDD And DLBNational Institute Of Neurological Disorders And Stroke2006
- Dementia With Parkinsonism: What Are We Diagnosing?National Institute On Aging1998–1999
- Dementia With Parkinsonism: What Are We Diagnosing?National Institute On Aging1998
- UnknownNational Institute On Aging1996–1997
- Dementia With Parkinsonism--What Are We Diagnosing?National Institute On Aging1995
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: